Protagenic Therapeutics, Inc.\new 8-K

What Happened
Protagenic Therapeutics, Inc. (PTIX) filed an 8‑K reporting that Nasdaq notified the company on December 31, 2025 that trading of its securities would cease at the close of trading on January 2, 2026, and Nasdaq’s delisting determination is final after the company withdrew its hearing request. The company expects its common stock (PTIX) and warrants (PTIXW) to be quoted on the over‑the‑counter (OTC) market beginning January 5, 2026, and says it will continue to file periodic and current reports with the SEC.

Key Details

• Nasdaq’s delisting was due to failure to meet continued listing requirements, including Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity) and Rule 5250(c)(1) (timely SEC filings).
• Nasdaq letter dated December 31, 2025: trading to cease after market close on January 2, 2026; company withdrew request for a hearing so the decision is final.
• Expected OTC quotation of PTIX and PTIXW beginning January 5, 2026; OTC trading is effected through registered broker‑dealers and may have different liquidity and trading characteristics than Nasdaq.
• Company intends to continue SEC reporting, evaluate steps to regain Nasdaq compliance, pursue possible relisting, and engage market participants to support liquidity.

Why It Matters
Delisting and a move to OTC can materially affect how easily investors can buy or sell PTIX or PTIXW and may reduce liquidity and visibility. Continued SEC reporting means investors can still access company disclosures on EDGAR, but relisting is not guaranteed—the company’s statements about OTC quotation and relisting are forward‑looking and subject to uncertainty as noted in the filing.